Acurx Pharmaceuticals (ACXP) Common Equity (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Common Equity came in at $7.0 million in Q1 2026, up 203.42% YoY from $2.3 million in Q1 2025, and up 33.11% on a QoQ basis from $5.3 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Common Equity (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Common Equity data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Common Equity rose 203.42% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 203.42% YoY) and the FY2025 annual result came in at $5.3 million, up 756.51% from the prior year.
- Common Equity climbed to $7.0 million in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $10.7 million in Q1 2022 to a low of $615121.0 in Q4 2024.
- A 5-year average of $5.4 million and a median of $5.3 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity sank 86.82% — and 2025, when it jumped 756.51%.
- Tracing ACXP's Common Equity over 5 years: stood at $7.3 million in 2022, then slumped by 36.2% to $4.7 million in 2023, then slumped by 86.82% to $615121.0 in 2024, then jumped by 756.51% to $5.3 million in 2025, then jumped by 33.11% to $7.0 million in 2026.
- The last three Common Equity figures came in at $7.0 million (Q1 2026), $5.3 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.15 Mn |
| Mar 31, 2026 | 7.01 Mn |
| Dec 31, 2025 | 5.27 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 3.57 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 615,121.00 |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 4.67 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 6.22 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 7.32 Mn |
| Sep 30, 2022 | 9.76 Mn |
| Jun 30, 2022 | 8.79 Mn |
| Mar 31, 2022 | 10.69 Mn |
| Dec 31, 2021 | 12.41 Mn |
| Sep 30, 2021 | 14.28 Mn |